Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Kappos L., Gold R., Miller D. H., MacManus D. G., Havrdova E., Limmroth V., ...More

LANCET, vol.372, no.9648, pp.1463-1472, 2008 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 372 Issue: 9648
  • Publication Date: 2008
  • Doi Number: 10.1016/s0140-6736(08)61619-0
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1463-1472
  • Istanbul University Affiliated: No


Background Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis.